Evolent Health
About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Employees: 4,700
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]
51% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 39
45% more capital invested
Capital invested by funds: $2.58B [Q2] → $3.73B (+$1.16B) [Q3]
7% more funds holding
Funds holding: 243 [Q2] → 260 (+17) [Q3]
2.33% less ownership
Funds ownership: 116.06% [Q2] → 113.73% (-2.33%) [Q3]
10% less call options, than puts
Call options by funds: $75.4M | Put options by funds: $84.2M
20% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 92
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
JMP Securities Constantine Davides 30% 1-year accuracy 9 / 30 met price target | 20%upside $12 | Market Outperform Reiterated | 14 Feb 2025 |
Needham Ryan MacDonald 56% 1-year accuracy 38 / 68 met price target | 50%upside $15 | Buy Reiterated | 12 Feb 2025 |
JP Morgan Anne Samuel 46% 1-year accuracy 16 / 35 met price target | 30%upside $13 | Overweight Maintained | 28 Jan 2025 |
Oppenheimer Jeff Jones 12% 1-year accuracy 5 / 41 met price target | 80%upside $18 | Outperform Maintained | 24 Jan 2025 |
Canaccord Genuity Richard Close 55% 1-year accuracy 16 / 29 met price target | 60%upside $16 | Buy Maintained | 23 Jan 2025 |
Financial journalist opinion
Based on 4 articles about EVH published over the past 30 days









